Navigation Links
Nephros Reports 2011 Fourth Quarter and Full Year Financial Results
Date:3/22/2012

share for the fourth quarter of 2011 versus a net loss of approximately $665,000 or $0.34 per basic and diluted common share in the fourth quarter of 2010. Nephros' net loss decreased $27,000 primarily due to an approximate $74,000 reduction in other expenses.  Other expense of approximately $15,000 in interest expense and $50,000 of debt issuance costs were incurred during the three months ended December 31, 2010. These expenses were not incurred during the three months ended December 31, 2011.

Outlook

Under the licensing agreement with Bellco, S.r.l., Nephros began 2012 with receipt of the second installment payment of euro 750,000 in January.  The third and final installment payment of euro 600,000 is payable to Nephros on January 15, 2013.  Beginning on January 1, 2015, Nephros will receive royalty payments from Bellco as part of the license agreement.

On August 11, 2011, Nephros filed a new 510(k) application with the FDA for clearance of the Company's hemodiafiltration (HDF) system for end-stage renal disease.   On November 8, 2011 the Company received the initial FDA review of its new 510(k) application (K112314), which included a request for additional information.  The Company provided answers to the FDA's request in early February 2012.  The Company's response is subject to the FDA's standard review period of 90 days; however, the Company has no assurance that a response will be received within this time period.  Nephros believes that, if approved, its technology would be the first FDA-approved on-line HDF therapy available in the U.S.

For 2011, Nephros recorded approximately $618,000 of sales related to its ultrafiltration products, a 23% increase over the prior year.  With the recent additions of Shane Sullivan as Director of U.S. Sales and Dr. Joseph Cervia as our strategic consultant, Nephros is working to formalize its marketing approach to the hospital infection control
'/>"/>

SOURCE Nephros, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
2. Nephros Reports 2009 Third Quarter Financial Results
3. Nephros Signs Canadian Distribution Agreement with Bellco Health Care Inc.
4. Nephros Signs Development Agreement with STERIS
5. Nephros Reports 2010 First Quarter Financial Results
6. Nephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems
7. Nephros Receives Formal Response from FDA for 510(k) Application for Hemodiafiltration System
8. Nephros Reports 2010 Second Quarter Financial Results
9. Nephros Completes Bridge Financing and Announces Stockholder Rights Offering
10. Nephros Reports 2010 Third Quarter Financial Results
11. Nephros Rights Offering Registration Statement Declared Effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... HILL, N.C. , July 11, 2014 /PRNewswire/ ... analysis approaches are evolving across industry sectors to ... now examining better ways to engage with and ... consumers inform themselves and make critical purchasing decisions. ... benchmarking firm, Best Practices, LLC, one area where ...
(Date:7/11/2014)... -- Research and Markets  has announced the addition ... report to their offering. ... hollow needle commonly used with a syringe to inject ... from it. A hypodermic needle is used for rapid ... be ingested. Hypodermic needles are broadly classified into non-safety ...
(Date:7/11/2014)... ALBANY, New York , July 11, 2014 /PRNewswire/ ... published by Transparency Market Research "Endoscopy Devices Market (Endoscopes, ... Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019" the ... billion in 2012 and is expected to grow at ... reach an estimated value of USD 36.9 billion in ...
Breaking Medicine Technology:New Technologies Transforming Consumer Marketing Research Playbook 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6
(Date:7/12/2014)... Wright & Schulte LLC has filed a DePuy Pinnacle ... Johnson & Johnson, on behalf of an Ohio man who ... DePuy Pinnacle hip replacement and had to undergo revision surgery ... DePuy hip lawsuit was filed July 7, 2014, in the ... where DePuy Pinnacle Hip lawsuit litigation is underway . ...
(Date:7/12/2014)... New York, NY (PRWEB) July 12, 2014 ... (the National Institute of Standards and Technology), the June ... up the electronic discovery world. It was ... was finally in, depending on whether it was seen from ... But this much is fact, there is now precedent ...
(Date:7/12/2014)... article released by Seattle's well known plastic surgeon, Dr. Bryan ... cosmetic surgical procedures in summer months . , As ... enliven the rainy Pacific Northwest, many people are turning their ... out as much during the winter as they had planned. ... eager to look their best for their summer vacations, and ...
(Date:7/12/2014)... Restore My Vision Today is a ... a couple boasting very impressive credentials on the field ... Today as a way to help consumers do without ... their respective patients’ treatments . , In ... trove of pertinent information relevant to eye care like:, ...
(Date:7/12/2014)... The largest pure occupational medicine company in the ... it will be opening its fifth Georgia center in ... Atlanta-based Nova Medical Centers’ locations. The Augusta facility ... and will be open from 8:30 a.m. to 6 ... philosophy of rapid return-to-work and decreased treatment times for ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 3Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 4Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 5Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 2Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 3Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 4Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 5Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 3Health News:Nova Medical Centers To Open New Facility in Augusta, Georgia 2
... Students to Get Fit By Finals, , Awards School with ... Chicago Bulls legend BJ Armstrong is rallying Chicago ... new national campaign called Get Fit By Finals . ... "got milk?" Body By Milk(R) Campaign and NBA FIT, the NBA,s ...
... galectin-3 may serve as treatment target against disease ... -- A newly identified marker for prostate cancer ... treatment, University of Michigan researchers say. , Previous ... marker galectin-3 are linked with neoplastic progression in ...
... Will Earn Decision Resources, Clinical Gold Standard Status ... a New Report from Decision ResourcesWALTHAM, Mass., March ... leading research and advisory firms for pharmaceutical and ... a therapy,s effect on the rate of mortality ...
... 2008 Frost & Sullivan European Human Growth ... to Ferring Pharmaceuticals. The award is in ... injection for human growth hormone (hGH). The ... VISION X, innovative no-needle delivery systems for ...
... WELLINGTON, Fla., March 25 The Quantum Group, Inc. ... announced it has implemented a reallocation of ... the PWeR(TM) (pronounced POWER) platform. As Quantum continues ... the Company expects for the PWeR platform, it has ...
... Osteoarthritis Sufferers to Live Fit by Thinking Fit, Eating ... 25 Today, Bob Greene, best-selling author and personal ... the 27 million Americans who suffer from osteoarthritis (OA) ... Pharmaceuticals (Nasdaq: ENDP ), the MOVE (Managing ...
Cached Medicine News:Health News:Got Milk?(R) and the NBA Showcase New National Teen Health and Fitness Initiative at Cesar E. Chavez Multicultural Center 2Health News:Got Milk?(R) and the NBA Showcase New National Teen Health and Fitness Initiative at Cesar E. Chavez Multicultural Center 3Health News:Got Milk?(R) and the NBA Showcase New National Teen Health and Fitness Initiative at Cesar E. Chavez Multicultural Center 4Health News:Got Milk?(R) and the NBA Showcase New National Teen Health and Fitness Initiative at Cesar E. Chavez Multicultural Center 5Health News:Surveyed Experts Indicate that Biogen Idec's Adentri Has Advantages Over Nitroglycerin in the Treatment of Acute Heart Failure 2Health News:Surveyed Experts Indicate that Biogen Idec's Adentri Has Advantages Over Nitroglycerin in the Treatment of Acute Heart Failure 3Health News:Frost & Sullivan Accolade for Ferring Pharmaceuticals 2Health News:Frost & Sullivan Accolade for Ferring Pharmaceuticals 3Health News:The Quantum Group Announces Resource Reallocation to Advance PWeR(TM) Platform 2Health News:The Quantum Group Announces Resource Reallocation to Advance PWeR(TM) Platform 3Health News:The Quantum Group Announces Resource Reallocation to Advance PWeR(TM) Platform 4Health News:The Quantum Group Announces Resource Reallocation to Advance PWeR(TM) Platform 5Health News:Exercise Physiologist and Celebrity Trainer Bob Greene Leads National Campaign to Showcase Osteoarthritis Pain Management Techniques and New Treatment Approaches 2Health News:Exercise Physiologist and Celebrity Trainer Bob Greene Leads National Campaign to Showcase Osteoarthritis Pain Management Techniques and New Treatment Approaches 3Health News:Exercise Physiologist and Celebrity Trainer Bob Greene Leads National Campaign to Showcase Osteoarthritis Pain Management Techniques and New Treatment Approaches 4Health News:Exercise Physiologist and Celebrity Trainer Bob Greene Leads National Campaign to Showcase Osteoarthritis Pain Management Techniques and New Treatment Approaches 5Health News:Exercise Physiologist and Celebrity Trainer Bob Greene Leads National Campaign to Showcase Osteoarthritis Pain Management Techniques and New Treatment Approaches 6Health News:Exercise Physiologist and Celebrity Trainer Bob Greene Leads National Campaign to Showcase Osteoarthritis Pain Management Techniques and New Treatment Approaches 7